Martela Corporation
12.10.2026 15:00:00 CEST | Globenewswire | Press release
Martela Corporation: Notification of change in holdings according to chapter 9, section 10 of the Securities Market Act
Martela Corporation: Notification of change in holdings according to chapter 9, section 10 of the Securities Market Act
Martela Corporation, stock exchange release on October 12, 2026, at 16:00 (EEST)
Martela Corporation has received a notification on October 12, 2026, referred to Chapter 9, Section 5 of the Securities Market Act. According to the notification, the voting rights held by Tuija Lindholm’s shares in Martela Corporation have decreased below the 5 % flagging threshold.
Total positions of person subject to the notification obligation:
| % of shares and voting rights (total of 7.A) | % of shares and voting rights through financial instruments (total of 7.B) | Total of both in % (7.A + 7.B) | Total number of shares and voting rights of the issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 0,40 | 0,40 | 20,698,114 | |
| Position of previous notification (if applicable) |
Notified details of the resulting situation on the date on which the threshold was crossed or reached:
| A: Shares and voting rights | ||||
| Class/type of shares | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI0009900385 | 82,123 | 0,40 | ||
| TOTAL | 82,123 | 0,40 | ||
Additional information notified by Tuija Lindholm:
On 29 September 2026, the Extraordinary General Meeting of Martela Corporation (the “Company”) resolved on the combination of the Company's share series (including the related amendment to the Articles of Association and the directed share issue without consideration), and on 30 September 2026, the Company's Board of Directors, based on the authorisation granted by the General Meeting, resolved on a directed share issue against consideration. In connection with the combination of the share series, the Company's previous series K shares were converted into shares of the Company's sole series of shares at a ratio of 1:1. At the same time, 151,195 new shares issued in the directed share issue without consideration to the holders of series K shares, and 15,907,707 new shares issued in the directed share issue against consideration, were entered in the Trade Register. The changes were registered on 12 October 2026, and the total number of shares in the Company increased to 20,698,114 shares. This flagging notification relates to the dilution of voting rights resulting from the arrangement, which caused the proportion of votes carried by the shares to fall below the 5% flagging threshold.
MARTELA CORPORATION
For more information, please contact:
Henri Berg, CFO, tel +358 40 836 5464
Distribution
Nasdaq Helsinki
Main news media
www.martela.com
Martela is a Nordic leader specialising in user-centric working and learning environments. With over 80 years of experience, we create the best places to work and offer our customers the Martela Lifecycle solutions which combine furniture and related services into a seamless whole.
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S24.10.2026 13:00:00 CEST | Press release
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
ASYAD24.10.2026 12:47:36 CEST | Press release
Asyad Group to Host Muscat Maritime Resilience Forum to Strengthen Global Trade Networks
King Faisal Specialist Hospital & Research Centre24.10.2026 11:00:00 CEST | Press release
KFSH Extends Emergency Access Through Virtual Care and Specialist Coordination
Orion Oyj24.10.2026 08:35:00 CEST | Press release
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
Zymeworks Inc.24.10.2026 08:30:00 CEST | Press release
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom